Joshua D - Search Results

1

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies.

Li EW, Jones E, Bryant C, King T, Talaulikar D, Ng JY, Bryant A, Ridha Z, Doo NW, Menzies A, Ling S, Ho SJ, Abadir E, Vanguru V, Joshua D, Ho PJ. Li EW, et al. Among authors: joshua d. Eur J Haematol. 2024 Oct;113(4):521-529. doi: 10.1111/ejh.14266. Epub 2024 Jul 2. Eur J Haematol. 2024. PMID: 38956924

2

The biology and cytogenetics of multiple myeloma.

Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. Ho PJ, et al. Among authors: joshua d. Rev Clin Exp Hematol. 2002 Sep;6(3):276-300. doi: 10.1046/j.1468-0734.2002.00081.x. Rev Clin Exp Hematol. 2002. PMID: 12616699 Review.

3

Multiple myeloma: challenges and opportunities.

Joshua D, Brown R, Ho PJ. Joshua D, et al. Methods Mol Med. 2005;113:1-4. doi: 10.1385/1-59259-916-8:1. Methods Mol Med. 2005. PMID: 15968090 Review. No abstract available.

4

Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?

Ling S, Joshua DE, Gibson J, Young G, Iland H, Watson G, Ho PJ. Ling S, et al. Am J Hematol. 2006 Feb;81(2):110-4. doi: 10.1002/ajh.20475. Am J Hematol. 2006. PMID: 16432856 Free article.

5

The use of thalidomide in myeloma therapy as an effective anticancer drug.

Sze DM, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. Sze DM, et al. Among authors: joshua d. Curr Cancer Drug Targets. 2006 Jun;6(4):325-31. doi: 10.2174/156800906777441762. Curr Cancer Drug Targets. 2006. PMID: 16848723 Review.

6

Regulatory T cells and multiple myeloma.

Joshua DE, Brown RD, Ho PJ, Gibson J. Joshua DE, et al. Clin Lymphoma Myeloma. 2008 Oct;8(5):283-6. doi: 10.3816/CLM.2008.n.039. Clin Lymphoma Myeloma. 2008. PMID: 18854282 Review.

7

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.

Brown RD, Spencer A, Ho PJ, Kennedy N, Kabani K, Yang S, Sze DM, Aklilu E, Gibson J, Joshua DE. Brown RD, et al. Among authors: joshua de. Leuk Lymphoma. 2009 Nov;50(11):1860-4. doi: 10.3109/10428190903216804. Leuk Lymphoma. 2009. PMID: 19883313 Clinical Trial.

8

Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy.

Li J, Sze DM, Brown RD, Cowley MJ, Kaplan W, Mo SL, Yang S, Aklilu E, Kabani K, Loh YS, Yamagishi T, Chen Y, Ho PJ, Joshua DE. Li J, et al. Among authors: joshua de. Blood. 2010 Apr 29;115(17):3580-8. doi: 10.1182/blood-2009-10-246991. Epub 2010 Feb 26. Blood. 2010. PMID: 20190191 Free article.

9

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD. Ling SC, et al. Among authors: joshua de. Haematologica. 2012 Jan;97(1):64-72. doi: 10.3324/haematol.2011.043331. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993678 Free PMC article.

10

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.

Ho PJ, Brown RD, Spencer A, Jeffels M, Daniher D, Gibson J, Joshua DE. Ho PJ, et al. Among authors: joshua de. Leuk Lymphoma. 2012 Sep;53(9):1728-34. doi: 10.3109/10428194.2012.664842. Epub 2012 Mar 13. Leuk Lymphoma. 2012. PMID: 22329352 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters